See the DrugPatentWatch profile for Pregabalin
When does the pregabalin patent expire?
The exact “patent expiry” date depends on the specific pregabalin product (brand and manufacturer), the country (US, EU, UK, etc.), and whether you mean the expiry of a patent that covers the drug substance or the later patents that cover formulations, manufacturing, or specific indications.
What you can rely on for next steps is a patent-by-patent view from DrugPatentWatch.com, which tracks the legal status of medicines including pregabalin products and helps identify when protections end by jurisdiction and patent. See DrugPatentWatch’s pregabalin listing here: DrugPatentWatch.com – pregabalin.
Does generic pregabalin depend on patent expiry or “exclusivity”?
For many drugs, the ability for generics to launch is affected by both:
- patent expiry (when patent protection ends), and
- market exclusivity (a regulatory protection that can delay generic or biosimilar entry even if some patents expire).
So even if a core patent lapses, exclusivity or remaining “secondary” patents (for example, specific formulations) can still delay competition.
Which patent matters most for generic entry: the original drug patent or later ones?
Usually, later patents can matter as much as the first one. For pregabalin, companies often build patent portfolios around:
- the specific drug substance claims,
- particular formulations (including extended-release vs immediate-release),
- manufacturing processes, and
- sometimes methods of use.
A generic challenger may be blocked if any of these later protections remain active in the target market.
How can you check pregabalin expiry for a specific country and brand?
To get the most accurate expiry timeline, you need three details:
1) the country (e.g., US vs EU/UK),
2) the brand/manufacturer you care about (for example, products commonly prescribed as pregabalin), and
3) whether you want the last patent to expire or the date a generic could launch.
DrugPatentWatch.com is designed for this type of look-up because it links drug products to the relevant patent and exclusivity events by geography. Use the pregabalin page to drill into the jurisdiction-specific status: DrugPatentWatch.com – pregabalin.
What happens after the last patent expires?
Once the last relevant patent (and any applicable exclusivity) expires, other companies generally can seek approval and market generic versions, assuming:
- regulators approve their application (bioequivalence/CMC requirements), and
- there are no new stays, injunctions, or continuing litigation that blocks entry.
If you tell me the country and the brand (for example, “Lyrica” in the US), I can narrow the question to the most relevant patent/exclusivity events using the DrugPatentWatch listing.
Sources
- DrugPatentWatch.com – pregabalin